Skip to main content

Table 2 Response evaluation in the All-Patients-Treated Set

From: SOX combined with intraperitoneal perfusion of docetaxel compared with DOS regimen in the first-line therapy for advanced gastric cancer with malignant ascites: a prospective observation

 

Overall evaluation

Evaluation of ascites

 

PR

ORR(%)

P

PR

ORR(%)

P

D-SOX (n = 39)

19

48.7

0.49

23

58.9

0.012

DOS (n = 39)

16

41.0

12

30.8

  1. ORR objective response rate
Back to article page

Trials

ISSN: 1745-6215